Status:
RECRUITING
A Study to Evaluate the Safety and Effectiveness Transdermal Compress Device in Participants With Transfemoral Amputations
Lead Sponsor:
Balmoral Medical company
Conditions:
Prosthesis and Implants
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of the Transdermal Compress device in participants with Transfemoral Amputations.
Detailed Description
This study is a prospective, multicenter, single-arm, open-label study in skeletally mature participants with transfemoral limb loss (unilateral or bilateral), without bone or vascular disease who hav...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Participant must be able to understand the investigational nature of this study and has reviewed and provided written, informed consent prior to any study-specific procedures.
- Participant is a skeletally mature male or female and is 18 - 60 years of age at screening. Participants \< 22 years of age require radiographic confirmation of skeletal maturity and must have failed the use of conventional prosthesis.
- Participant has an estimated BMI of ≥ 18.5 and ≤ 40 kg/m2 and weight ≤ 245 lbs without prosthesis.
- Participant has unilateral or bilateral transfemoral limb loss without bone or vascular disease.
- Participant has problems with conventional prostheses or is not able to use a prosthesis at all or is anticipated to experience problems with a socket prosthesis in the investigator's judgment.
- Participant has adequate bone stock to support the implanted device
- Participant does not have any cortical defect located between the expected location of the anchor plug and spindle/bone interface.
- Participant has the willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program.
- Exclusion Criteria
- Female participants who are pregnant, nursing, or have a planned pregnancy during the first 12 months post-surgical implantation.
- Participant had a prior osseointegrated device implanted in the lower limb planned for the study device.
- Participant has a history of systemic or localized infection at the residual limb site within 6 months prior to Study Day 1.
- Participant has any distant foci of infections.
- Participant has a history of sepsis within 6 months prior to Study Day 1.
- Participant's length of the residual femur cannot accommodate the intramedullary portion of the Transdermal Compress device.
- Participant has a femoral deformity that in the opinion of the treating surgeon results in an inability to properly insert the Transdermal Compress implant system, and/or results in alignment that is biomechanically unsound.
- Participant does not have an adequate myofascial flap to allow for circumferential contact with the implanted device.
- Participant has evidence of or history of severe peripheral vascular disease or insufficiency, muscular atrophy, neuromuscular disease, or diabetes mellitus (Type I or Type II).
- Participant has evidence of or a documented history of osteomyelitis (excluding the history of osteomyelitis distal to amputation), systemic osteoporosis, or osteomalacia.
- Participants with identified risk factors for osteoporosis must have a reported T-score \> -2.5 within 6 months prior to Study Day 1.
- Participant has evidence of or a documented history of severe metabolic disorders that may impair bone formation.
- Participant has a history of systemically administered corticosteroids or immunosuppressive or immunomodulatory therapy or chemotherapy drugs.
- Participant has known drug or alcohol dependence currently or within the last year.
- Participant is a smoker, nicotine, or tobacco user in any form or who has used nicotine or tobacco-containing products within the past 6 months prior to Study Day 1.
- Participant has any other condition, which in the opinion of the Investigator, precludes the participant's participation in the study or the participant is unlikely to comply with the protocol-defined
Exclusion
Key Trial Info
Start Date :
June 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2031
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06134167
Start Date
June 11 2024
End Date
June 1 2031
Last Update
January 7 2026
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis Medical Center
Sacramento, California, United States, 95817
2
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
3
Walter Reed Military Medical Center
Washington D.C., District of Columbia, United States, 20814
4
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611